nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-A5CA6E6E·Framework v5.9·Pipeline v0.4·Evaluated 22 Sept 2026·OECD: 3.2 Clinical medicine·Subfield: Genetics·Basis: Full text·Type: Cross-sectional study

In Search of an Association Between Genotype and Phenotype in Hereditary Angioedema due to C1-INH Deficiency

David Loli-Ausejo et al.David Loli-Ausejo, Alberto López-Lera, Christian Drouet et al.·2021·Clinical Reviews in Allergy & Immunology·10.1007/s12016-021-08834-9 ↗

Primary claim

Our study shows minimal differences regarding clinical phenotype in patients with class 0, II, and III SERPING1 gene mutations, with a tendency to class III having a more severe phenotype.

Supported · class-pure comparisons are mostly null, though small unadjusted groups limit precision
In brief

A useful exploratory genotype–phenotype study that organizes a fragmented rare-disease literature, but its small unadjusted single-center analysis limits inference.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract not available — view at DOI ↗

Key Claims

Primary finding · Supported

Our study shows minimal differences regarding clinical phenotype in patients with class 0, II, and III SERPING1 gene mutations, with a tendency to class III having a more severe phenotype.

Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

class-pure comparisons are mostly null, though small unadjusted groups limit precision

Abstract; Discussion, “Genotype–Phenotype Associations According to a New Classification Proposal”
Quote verified
Secondary · Tentative

The use of a new classification of the SERPING1 gene mutations demonstrated a difference in the levels of antigenic C4 and C1 inhibitor and the number of HAE facial attacks among the different SERPING1 gene mutation classes.

small observational groups and numerous unadjusted comparisons weaken the isolated nominal differences

Conclusion
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#positioning

Balanced synthesis of conflicting prior studies

Table 4 and the Discussion include studies reporting both positive and null genotype–phenotype associations, positioning the cohort within a genuinely mixed evidence base.

↳ Table 4; Discussion, “Genotype–Phenotype Associations According to Present SERPING1 Gene Mutation Classifications”

#reporting

Cautious framing of preliminary findings

The Abstract and Discussion describe minimal differences, use “tendency” language, and explicitly call for larger samples rather than presenting the associations as definitive.

↳ Abstract; Discussion, “Genotype–Phenotype Associations According to a New Classification Proposal”

#methodological rigour

Transparent classification and outcome tables

Tables 1–3 show mutation assignments, cohort characteristics, class-pure analytic groups, and individual comparison p values, while the Methods identify the validated HAE-AS measure.

↳ Materials and Methods; Tables 1–3

Limitations

#methodological rigour

Unadjusted comparisons leave major uncertainty

The statistical analysis relies on chi-squared and Kruskal–Wallis tests without covariate or family-cluster adjustment, despite potential differences in age, treatment, relatedness, and disease history across mutation classes.

↳ Materials and Methods, statistical analysis; Table 3

#methodological rigour

Multiple testing weakens positive findings

Table 3 reports numerous unadjusted comparisons, making the isolated p=0.040 facial-attack result and laboratory differences hypothesis-generating rather than confirmatory.

↳ Table 3; Abstract

#application pathway

Single-center sample limits generalization

Participants were adults followed at one Spanish allergy department, and the analysis provides no external validation or sensitivity analysis across populations.

↳ Materials and Methods, patient selection; Table 4

Does this match your read? Add your assessment ↓

Nabu Commentary

The modified mutation classification and detailed tables provide a transparent exploratory contribution to a difficult rare-disease question. Most class-pure comparisons in Table 3 are null, and the paper appropriately presents the overall phenotype differences as minimal. The evidentiary weight of the positive laboratory and facial-attack findings is reduced by small groups, many unadjusted tests, and the absence of multivariable or family-aware analysis. Table 4 supplies useful cumulative context, but the current results remain hypothesis-generating rather than clinically actionable.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.9±0.2

Contribution
2.7

The modified structural mutation classification and accompanying Spanish cohort add an identifiable but incremental perspective. The predominantly null result does not resolve the conflicting genotype–phenotype evidence summarized by the paper.

Discussion, “Genotype–Phenotype Associations According to a New Classification Proposal”; Table 4

Our study shows minimal differences regarding clinical phenotype

Methodological Rigour
2.5

Sanger genotyping, the validated HAE-AS instrument, and transparent group tables fit the descriptive question. Crude comparisons without covariate adjustment, referral-bias analysis, or quantified classification uncertainty materially limit inference.

Materials and Methods; Tables 1 and 3
Reporting
3.8

The argument proceeds coherently from biological rationale through classification, comparisons, and a cautious call for confirmation. Minor count and p-value inconsistencies, plus stronger wording in the Conclusion, reduce reporting precision.

Abstract; Results; Tables 2–3; Conclusion

The study should be performed in a larger sample to confirm if they are significant.

Positioning
3.5

The paper maps 12 positive and null genotype–phenotype studies and identifies heterogeneous classifications and outcome measures as barriers to comparison. Its limitations discussion acknowledges sample size but does not fully trace multiplicity or other analytic constraints into the nominal findings.

Table 4; Discussion, genotype–phenotype review and limitations

our study has the limitation of a small sample of patients

Reliability

Caveats4 of 4 checks


Internal CoherenceNoted

Several minor reporting and cohort-accounting inconsistencies are reconcilable or do not change the overall interpretation, but they reduce reporting precision. The broad set of unadjusted comparisons also warrants caution when interpreting isolated nominally significant results.

Research ConductClean

Ethics approval, written informed consent, conflict-of-interest disclosure, funding, and a data-availability statement are reported. No text-grounded research-conduct concern was identified.

Flags: 3 declared / 5 total

Reference IntegrityClean

26 of 26 checkable references verified

26 references in manuscript

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Metabolic and endocrine · Endocrine, metabolic, blood, and immune disorders
Type of advanceEmpirical
Route to useNot stated
AdvanceExtends
BeneficiariesCatch-all cause
CitationsFWCI 0.8
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The claim rests on one observational single-center cohort of 88 patients with mostly non-significant differences and no controlled or independent confirmation.

The paper proposes only larger multicenter research studies and states no real-world application of its own findings.

Pathway

If multicenter studies confirm genotype-phenotype associations, allergists and clinical geneticists could use SERPING1 mutation class to predict severity and guide C1-INH-HAE management.

Barrier

The small single-center cohort yields mostly non-significant differences, so large multicentre replication is needed before mutation class could inform any clinical decision.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks

    Riedl, Farkas, Aygören-Pürsün, et al. · 2024 · Clinical medicine

    Primary claim

    Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.

    Well-supported
    Evidence Score
    4.2±0.2
    Reliability
    No concerns
  2. Efficacy and Safety of Donidalorsen for Hereditary Angioedema

    Riedl, Tachdjian, Lumry, et al. · 2024 · Clinical medicine

    Primary claim

    Donidalorsen at a dose of 80 mg administered subcutaneously every 4 or 8 weeks significantly reduced the hereditary angioedema attack rate

    Supported
    Evidence Score
    4.0±0.1
    Reliability
    Caveats
  3. CRISPR-Based Therapy for Hereditary Angioedema

    Cohn, Gurugama, Magerl, et al. · 2024 · Clinical medicine

    Primary claim

    NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema.

    Tentative
    Evidence Score
    3.6±0.1
    Reliability
    Caveats

How the rubric works →